Biotechnology company Windtree Therapeutics is being delisted from the Nasdaq stock exchange. Windtree Therapeutics recently shared its goal of becoming “BNB's Microstrategy.” The company was officially put on notice on August 19, 2025, for failing to meet the minimum share price requirement established under Nasdaq Listing Rule 5550(a)(2). Nasdaq announced that Windtree's shares, ticker symbol WINT, will cease trading at market open on August 21, 2025. The company's shares are expected to begin trading on the OTC (over-the-counter) market on the same day. Windtree stated that it has applied to OTC Markets' OTCQB platform, but approval is not guaranteed. Windtree Therapeutics stated that this transition will not impact its operations and that it will continue to file reports with the U.S. Securities and Exchange Commission (SEC). The company has previously warned investors about potential risks and uncertainties in documents filed with the SEC. The price of BNB broke its all-time high today. At the time of writing, the coin is trading at $873, a record high. *This is not investment advice.